<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cocrystal Pharma Inc — News on 6ix</title>
    <link>https://6ix.com/company/cocrystal-pharma-inc</link>
    <description>Latest news and press releases for Cocrystal Pharma Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/cocrystal-pharma-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835580478dffbe2df0ea6d6.webp</url>
      <title>Cocrystal Pharma Inc</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc</link>
    </image>
    <item>
      <title>Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-receives-fda-fast-track-designation-for-cdi-988-for-norovirus-infection-treatment-and-preventive-101</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-receives-fda-fast-track-designation-for-cdi-988-for-norovirus-infection-treatment-and-preventive-101</guid>
      <pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
      <description>FDA Fast Track designation supports accelerated development and expedites regulatory reviewNorovirus is responsible for an estimated 685 million global cases</description>
    </item>
    <item>
      <title>Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-reports-2025-financial-results-and-provides-updates-on-its-antiviral-drug-development-programs</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-reports-2025-financial-results-and-provides-updates-on-its-antiviral-drug-development-programs</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral candidate being developed for</description>
    </item>
    <item>
      <title>First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/first-subjects-dosed-in-cocrystal-pharmas-phase-1b-study-evaluating-cdi-988-for-norovirus-prevention-and-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/first-subjects-dosed-in-cocrystal-pharmas-phase-1b-study-evaluating-cdi-988-for-norovirus-prevention-and-treatment</guid>
      <pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
      <description>CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory University School of Medicine to</description>
    </item>
    <item>
      <title>Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharmas-first-oral-norovirus-protease-inhibitor-cdi-988-to-be-featured-at-the-international-society-for-antiviral-research-conference-icar-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharmas-first-oral-norovirus-protease-inhibitor-cdi-988-to-be-featured-at-the-international-society-for-antiviral-research-conference-icar-2026</guid>
      <pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
      <description>CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infectionsCompany to present Phase 1 data and</description>
    </item>
    <item>
      <title>Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-receives-irb-approval-130000723</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-receives-irb-approval-130000723</guid>
      <pubDate>Thu, 18 Dec 2025 13:00:00 GMT</pubDate>
      <description>Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis caused by norovirus infectionThere are no approved treatments or vaccines currently available for norovirus infection BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the approval from the Institutional Review Boar</description>
    </item>
    <item>
      <title>Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-present-noble-capital-130000460</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-present-noble-capital-130000460</guid>
      <pubDate>Mon, 01 Dec 2025 13:00:00 GMT</pubDate>
      <description>BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview and clinical progress update at NobleCon 21 – Noble Capital Markets 21st Emerging Growth Equity Conference on Wednesday, December 3, 2025 at 10:00 am Eastern time. The conference is being held at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida. Interested investors</description>
    </item>
    <item>
      <title>Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-reports-third-quarter-130000358</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-reports-third-quarter-130000358</guid>
      <pubDate>Fri, 14 Nov 2025 13:00:00 GMT</pubDate>
      <description>Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b norovirus challenge study in Q1 2026 Granted NIH SBIR award to advance influenza A/B replication inhibitor program BOTHELL, Wash., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and nine months ended September 30, 2025, and provides updates on its antiviral product pipeline, up</description>
    </item>
    <item>
      <title>Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-insiders-purchase-1-120000540</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-insiders-purchase-1-120000540</guid>
      <pubDate>Thu, 30 Oct 2025 12:00:00 GMT</pubDate>
      <description>Investment by Directors and Management demonstrates confidence in the Company Potential for an additional $1.8 million upon the exercise in full of warrants BOTHELL, Wash., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (the “Company” or “Cocrystal”) announces the completion of a private placement of units priced at-the-market under Nasdaq rules with 743,024 shares of its common stock at a purchase price of $1.39 per unit for proceeds of $1.03 million and unregistered wa</description>
    </item>
    <item>
      <title>Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-receives-nih-sbir-120000590</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-receives-nih-sbir-120000590</guid>
      <pubDate>Mon, 27 Oct 2025 12:00:00 GMT</pubDate>
      <description>BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received a Small Business Innovation Research (SBIR) Phase I award from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID). This approximately $500,000 award will support the Company’s development of a novel, oral, broad-spectrum antiviral candidate for the treatment of influenza A and B infections. Cocrystal pl</description>
    </item>
    <item>
      <title>Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-present-noble-capital-120000776</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-present-noble-capital-120000776</guid>
      <pubDate>Thu, 02 Oct 2025 12:00:00 GMT</pubDate>
      <description>BOTHELL, Wash., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview at the Noble Capital Markets Emerging Growth Virtual Equity Conference on Thursday, October 9, 2025 at 12:00 pm Eastern time (9:00 a.m. Pacific time). The formal presentation will be followed by a hosted question-and-answer session with questions welcomed from the live virtual audience. Those interested</description>
    </item>
    <item>
      <title>Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-inc-announces-closing-203000038</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-inc-announces-closing-203000038</guid>
      <pubDate>Mon, 15 Sep 2025 20:30:00 GMT</pubDate>
      <description>$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., (Nasdaq: COCP) (the “Company” or “Cocrystal”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,764,710 shares of its common stock at a purchase price of $1.70 per share.</description>
    </item>
    <item>
      <title>Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-inc-announces-13-134300137</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-inc-announces-13-134300137</guid>
      <pubDate>Fri, 12 Sep 2025 13:43:00 GMT</pubDate>
      <description>$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., (Nasdaq: COCP) (the “Company” or “Cocrystal”), today announced that it has entered into definitive agreements for the purchase and sale of 2,764,710 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.70 per share in a registered</description>
    </item>
    <item>
      <title>Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-showcases-cdi-988-120000277</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-showcases-cdi-988-120000277</guid>
      <pubDate>Fri, 12 Sep 2025 12:00:00 GMT</pubDate>
      <description>BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress with the Company’s lead pan-viral protease inhibitor CDI-988 during a podium presentation at the 9th International Calicivirus Conference, held September 7–11, 2025 in Banff, Alberta. Based on a novel mechanism of action and superior broad-spectrum antiviral activity, CDI-988 represents a potential firs</description>
    </item>
    <item>
      <title>Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-receives-fda-ind-120000019</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-receives-fda-ind-120000019</guid>
      <pubDate>Mon, 08 Sep 2025 12:00:00 GMT</pubDate>
      <description>There are currently no approved vaccines or treatments for norovirus infectionCocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by norovirus infections Phase 1b study is expected to start by year-end 2025 BOTHELL, Wash., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the Company received a Study May Proceed Letter from the U.S. Food and Drug Administration (</description>
    </item>
    <item>
      <title>Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-participate-h-c-120000537</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-participate-h-c-120000537</guid>
      <pubDate>Wed, 03 Sep 2025 12:00:00 GMT</pubDate>
      <description>BOTHELL, Wash., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025 at 12:00 p.m. Eastern time. Mr. Martin will be available throughout the conference for in-person and virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the c</description>
    </item>
    <item>
      <title>Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-reports-second-quarter-120000352</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-reports-second-quarter-120000352</guid>
      <pubDate>Thu, 14 Aug 2025 12:00:00 GMT</pubDate>
      <description>Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and six months ended June 30, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. “Preparations are underway for a Phase 1b norovirus</description>
    </item>
    <item>
      <title>Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-presents-phase-1-120000614</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-presents-phase-1-120000614</guid>
      <pubDate>Tue, 05 Aug 2025 12:00:00 GMT</pubDate>
      <description>All CDI-988 doses, ranging from 100 mg to 1200 mg, in the Phase 1 study were well toleratedCompany expects to initiate Phase 1b study with CDI-988 in norovirus-infected healthy subjects later this yearLack of approved norovirus treatments or vaccines creates critical unmet medical need BOTHELL, Wash., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the presentation of favorable safety and tolerability data from a randomized, double-blinded, placebo-controlled Ph</description>
    </item>
    <item>
      <title>Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-present-data-phase-120000007</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-present-data-phase-120000007</guid>
      <pubDate>Thu, 10 Jul 2025 12:00:00 GMT</pubDate>
      <description>BOTHELL, Wash., July 10, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for an oral presentation at the 9th International Calicivirus Conference being held September 7-11, 2025 in Banff, Alberta, Canada. Sam Lee, PhD, the Company’s President and co-CEO, will present “Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: Mechanism of Action and Phase 1 Study Re</description>
    </item>
    <item>
      <title>Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-novel-norovirus-antiviral-120000860</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-novel-norovirus-antiviral-120000860</guid>
      <pubDate>Thu, 05 Jun 2025 12:00:00 GMT</pubDate>
      <description>BOTHELL, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the 2025 Military Health System Research Symposium (MHSRS) being held August 4-7 in Kissimmee, Fla. Cocrystal is developing CDI-988 as a norovirus prophylaxis and treatment. Sam Lee, PhD, the Company’s President and co-CEO, will discuss Phase 1 results during the Broad-Spectrum Anti-Viral Countermeasures b</description>
    </item>
    <item>
      <title>Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain</title>
      <link>https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-investigational-drug-candidate-120000646</link>
      <guid isPermaLink="true">https://6ix.com/company/cocrystal-pharma-inc/news/cocrystal-pharma-investigational-drug-candidate-120000646</guid>
      <pubDate>Thu, 29 May 2025 12:00:00 GMT</pubDate>
      <description>CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company’s virology study further confirmed the previous structural and in vitro data that revealed the binding of CC-42344 to PB2 protein of the 2024 H5N1 avian influenza virus BOTHELL, Wash., May 29, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that a recent virology study showed its novel, broad-spectrum influenza PB2 inhibitor CC-42344 exhibits strong ant</description>
    </item>
  </channel>
</rss>